To include your compound in the COVID-19 Resource Center, submit it here.

Fidaxomicin meets Phase III endpoint

Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) said fidaxomicin ( OPT-80) was non-inferior to Vancocin vancomycin on

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE